Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics

被引：0
|
作者：
窦雪琳 [1 ]
机构：
[1] Peking Univ People’s Hosp,Peking Univ Hematol Instit
来源：
China Medical Abstracts(Internal Medicine) | 2020年 / 37卷 / 01期
关键词：
Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics;
D O I：
暂无
中图分类号：
R733.72 [慢性白血病];
学科分类号：
摘要：
Objective To compare the efficacy and safety of Chinese generic imatinib with branded imatinib as frontline therapy in adults with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)(Frontline group),and to explore the efficacy and safety of Chinese generic imatinib in CML-CP patients switching from branded imatinib (Switching group).Methods Frontline group:Data of adults with newly diagnosed CML-CP re-
引用
收藏
页码：59 / 60
页数：2
相关论文
共 50 条
  • [1] Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study
    Dou, Xuelin
    Qin, Yazhen
    Lai, Yueyun
    Shi, Hongxia
    Huang, Xiaojun
    Jiang, Qian
    BLOOD, 2019, 134
  • [2] Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China
    Cheng, Fang
    Wu, Di
    Cui, Zheng
    Li, Qiang
    Li, Weiming
    Zhang, Yu
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [3] Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center
    Dou, Xuelin
    Qin, Yazhen
    Lai, Yueyun
    Shi, Hongxia
    Huang, Xiaojun
    Jiang, Qian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (06): : E304 - E315
  • [4] Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy
    Bonifacio, Massimiliano
    Scaffidi, Luigi
    Binotto, Gianni
    Miggiano, Maria Cristina
    Danini, Marco
    Minotto, Claudia
    Griguolo, Davide
    Marin, Luciana
    Frison, Luca
    D'Amore, Fabio
    Basso, Marco
    Sartori, Roberto
    Tinelli, Martina
    Stulle, Manuela
    Fortuna, Stefania
    Bonalumi, Angela
    Bertoldero, Giovanni
    De Biasi, Ercole
    Ruggeri, Marco
    Semenzato, Gianpietro
    Fanin, Renato
    Pizzolo, Giovanni
    Krampera, Mauro
    Tiribelli, Mario
    LEUKEMIA RESEARCH, 2018, 74 : 75 - 79
  • [5] A comparison of efficacy and safety between Chinese generic imatinib and branded imatinib in patients with newly-diagnosed chronic myeloid leukemia in the chronic phase:a single-center prospective cohort study
    石红霞
    China Medical Abstracts(Internal Medicine), 2017, 34 (01) : 57 - 57
  • [6] Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia
    Aboudalle, Iman
    Kantarjian, Hagop M.
    Burger, Jan A.
    Estrov, Zeev
    Ohanian, Maro
    Jabbour, Elias J.
    Verstovsek, Srdan
    Ravandi, Farhad
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [7] EVALUATION OF CLINICAL EFFICACY AND SAFETY OF GENERIC IMATINIB IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
    Cojbasic, I.
    Macukanovic-Golubovic, L.
    Vucic, M.
    Govedarovic, N.
    HAEMATOLOGICA, 2016, 101 : 734 - 735
  • [8] Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center (vol 20, pg e304, 2020)
    Dou, Xuelin
    Qin, Yazhen
    Lai, Yueyun
    Shi, Hongxia
    Huang, Xiaojun
    Jiang, Qian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (01): : E84 - E84
  • [9] Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
    Abou Dalle, Iman
    Kantarjian, Hagop
    Burger, Jan
    Estrov, Zeev
    Ohanian, Maro
    Verstovsek, Srdan
    Ravandi, Farhad
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Cortes, Jorge
    CANCER MEDICINE, 2019, 8 (15): : 6559 - 6565
  • [10] Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients
    Emilia Scalzulli
    Gioia Colafigli
    Roberto Latagliata
    Sara Pepe
    Daniela Diverio
    Francesca Stocchi
    Alessio Di Prima
    Fabio Efficace
    Maurizio Martelli
    Robin Foà
    Massimo Breccia
    Annals of Hematology, 2020, 99 : 2773 - 2777
12345